Bioventus Inc. filings document the formal disclosures of a Nasdaq-listed medical device company with Class A common stock registered under the Exchange Act. Recent Form 8-K reports furnish operating results and financial condition updates, including quarterly and annual earnings releases for the company’s active-healing product portfolio.
The company’s regulatory filings also cover proxy governance for annual stockholder meetings, board composition matters, emerging growth company status, credit arrangements entered into by Bioventus LLC and its subsidiaries, and product regulatory events such as FDA 510(k) clearance for TalisMann and StimTrial within the Peripheral Nerve Stimulation portfolio.
Bioventus Inc. reported stronger quarterly results, returning to profitability. Net sales rose to $132.1 million, up 6.6% year over year, driven by growth in Pain Treatments and Surgical Solutions in both U.S. and international markets.
The company generated net income of $3.9 million versus a $3.3 million loss a year ago, with diluted EPS of $0.04. Gross margin improved to 68.7%, and Adjusted EBITDA increased to $23.9 million from $19.2 million.
Operating cash flow improved to $8.9 million, enabling a discretionary $22.0 million prepayment on the 2025 Term Loan. The term loan balance was $274.3 million before discounts, and cash and cash equivalents were $35.8 million. The company remained in compliance with its credit covenants.
Bioventus Inc. reported stronger first-quarter 2026 results, with revenue of $132.1 million, up 6.6% year over year, driven by growth across Pain Treatments, Surgical Solutions and Restorative Therapies.
Net income attributable to Bioventus was $3.1 million, reversing a $2.6 million loss a year earlier, and GAAP diluted EPS improved to $0.04 from a $0.04 loss. Non-GAAP diluted EPS rose to $0.15 from $0.08, supported by higher gross profit, lower interest expense and a 24% increase in Adjusted EBITDA to $23.9 million.
Cash from operations was $8.9 million, compared with a $19.3 million outflow in the prior-year quarter. The company made a $22.0 million discretionary term-loan prepayment and raised full-year 2026 guidance for Adjusted EPS to $0.75–$0.79 and cash from operations to $84–$89 million, while reaffirming net sales guidance of $600–$610 million, implying approximately 6%–7% growth.
Bioventus files a comprehensive annual report describing its business, product portfolio, regulatory environment and principal risks. The company reports U.S. and International segments representing 88% and 12% of net sales for the year ended December 31, 2025, and lists core areas: Pain Treatments, Surgical Solutions and Restorative Therapies. The filing notes FDA 510(k) clearances for TalisMann and StimTrial in July 2025 and a limited commercial release in Q3 2025, followed by a broader launch in early 2026. It discloses intellectual property counts, manufacturing and supply constraints, key regulatory frameworks (U.S. FDA, EU MDR), material legal and reimbursement risks, and that the company had approximately 930 employees as of December 31, 2025.
Bioventus Inc. is asking stockholders to vote at its 2026 virtual Annual Meeting on June 3, 2026 at 10:00 a.m. Eastern Time. Holders of 67,638,295 shares of Class A and 15,786,737 shares of Class B common stock as of April 6, 2026 may vote, with each share receiving one vote.
Stockholders will elect twelve directors to one-year terms and vote on ratifying Grant Thornton LLP as independent auditor for 2026. The proxy details board and committee composition, director independence, governance policies, a Dodd-Frank–aligned compensation clawback, and sizeable equity incentive and employee stock purchase plans supporting long-term equity-based compensation.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. filed an amended insider report for director Philip G. Cowdy to correct a previously reported grant of 2,700 Restricted Stock Units dated April 1, 2021. A footnote explains the earlier Form 4 was filed inadvertently for RSUs that were not accepted, and that as of April 1, 2021, Cowdy held no non-derivative or derivative securities of Bioventus.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. director Philip G. Cowdy filed an amended insider report to correct a previously reported equity grant. A prior Form 4 had shown a grant of 9,000 restricted stock units, but the footnote explains this grant was not accepted. As of February 11, 2021, he held no non-derivative or derivative securities of Bioventus.
Bioventus Inc. senior vice president and CFO Mark Leonard Singleton reported routine equity compensation activity involving Class A common stock and restricted stock units. On April 10, 2026, he exercised 13,000 restricted stock units, receiving an equal number of Class A shares at a conversion price of $0.00 per share.
To cover related tax obligations, 5,648 Class A shares were disposed of through a tax-withholding transaction at $9.06 per share, a non‑market “F” code event rather than an open‑market sale. After these transactions, Singleton directly owned 182,981 Class A shares, reflecting a net increase in his equity position from this vesting and withholding sequence.
Bioventus Inc. executive Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026, receiving 4,300 shares of Class A common stock at a conversion price of $0.00 per share. Of these, 1,868 shares of Class A common stock were withheld at $9.06 per share to satisfy tax obligations, a non-market tax-withholding disposition. After these transactions, she directly owned 64,164 shares of Class A common stock. The footnotes explain that each RSU represents a right to receive one share of Class A common stock and that the RSUs vest in four equal installments on each of the first four anniversaries of April 10, 2023, subject to continued service.
Bioventus Inc. SVP & General Counsel Anthony D'Adamio exercised restricted stock units into shares of Class A common stock. On April 10, 2026, he converted 9,925 RSUs into 9,925 shares of Class A common stock at a conversion price of $0.00 per share.
To cover tax obligations related to this equity compensation, 4,312 shares of Class A common stock were disposed of at $9.06 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 153,655 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported routine equity compensation activity in the form of restricted stock units. On March 20, 2026, he exercised 18,625 RSUs, receiving the same number of shares of Class A common stock at a stated price of $0.00 per share.
To cover tax obligations related to this vesting, 8,091 shares of Class A common stock were withheld at $8.64 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Singleton directly held 169,981 shares of Class A common stock.